One Day Advisor

By One Day Advisor Editorial Team | Reviewed by: Frank Yap, MBA | Originally published: June 2025 | Last updated: November 2, 2026 (company results through the Oct 30, 2026 close of Q3 reporting; Novo Nordisk and Vertex report this week) Quick Answer Counting Mounjaro and Zepbound together, Eli Lilly’s tirzepatide was the world’s best-selling drug in 2025 at $36.51 billion . Novo Nordisk’s semaglutide (Ozempic plus Wegovy, about $31.8B) edged Merck’s Keytruda ($31.68B), the top single brand. The 20 drug franchises below generated about $289 billion. In Q3 2026, Mounjaro alone ($10.7B) out-earned Keytruda ($8.6B). What changed in this update: expanded from a Top 10 to a Top 20; combined Mounjaro and Zepbound (tirzepatide) and Ozempic and Wegovy (semaglutide) into single franchise entries; refreshed with Q3 2026 earnings; corrected the 2024-to-2025 movers (Zepbound entered...

Investing › AI Tools › Updated October 2026 · Originally published July 30, 2026 Reviewed by: Frank Yap, MBA | Written by: One Day Advisor Editorial Team Quick Answer There is no single best AI for investment research in 2026. AlphaSense and Hebbia serve institutions, and ChatGPT for Financial Services is limited to eligible financial institutions. Most individual investors do well with Perplexity Finance for cited, real-time answers, Claude or ChatGPT for reading filings and building models, and Koyfin or TIKR for data. Verify every figure against the primary filing before acting. What changed in the October 2026 update AlphaSense raised $350 million at a $7.5 billion valuation (June 2026), reported ARR above $600 million, and added the SuperAnalyst agent plus Excel and PowerPoint assistants. Perplexity added brokerage ...